How to manage tumor flare after administration of bispecific antibodies 

Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, discusses the management of tumor flare, a frequently observed complication following the administration of T-cell-engaging bispecific antibodies. The risk of developing this adverse event should be identified prior to initiating therapy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.